EpiVax is an immunology company and has developed comprehensive analytical capabilities in the field of computational immunology.
We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines.
We leverage our proprietary tools and expertise, thereby adding value to our clients’ research and development efforts while applying them to our own pipeline of therapeutic proteins and vaccine candidates.
EpiVax understands the scientific, financial, and regulatory challenges faced by today’s pharmaceutical industry and applies this knowledge at every step from design, to execution, and to IND.
Click the picture below to read our published company overview.